



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

27<sup>th</sup> March, 2025

Corporate Relationship Department  
The Bombay Stock Exchange Limited  
Dalal Street, Fort  
Mumbai 400 001

The Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

**Sub:-** Disclosure under Regulations 29(2) of the SEBI (Substantial acquisition of shares and Takeovers) Regulations 2011 and Form C of the SEBI (Prohibition of Insider Trading) Regulations, 2015

**Ref :-** Natco Pharma Limited

Please find enclosed herewith the disclosures received from Mr. Sanjay Nannapaneni, Member of Promoter Group under Regulations 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 pertaining to the transmission of Shares from Late Ramakrishna Rao Nannapaneni, Member of Promoter Group.

This is for your information and records.

Thanking you

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

27<sup>th</sup> March, 2025

Corporate Relationship Department  
The Bombay Stock Exchange Limited  
Dalal Street, Fort  
Mumbai 400 001

The Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

**Sub:-** Disclosure under Regulations 29(2) of the SEBI (Substantial acquisition of shares and Takeovers) Regulations 2011 and Form C of the SEBI (Prohibition of Insider Trading) Regulations, 2015

**Ref :-** Natco Pharma Limited

With reference to the above cited subject, I hereby disclose that 2,86,910 equity shares of Rs.2/- each held by Late Ramakarishna Rao Nannapaneni, Member of Promoter Group of NATCO Pharma Limited were transmitted to me on 26<sup>th</sup> March, 2025.

The said shares were transmitted to me pursuant to the registered Will Deed of my father via Off-Market Transaction by using “Code 21 i.e., Transfer from Nominee/Surviving holder to beneficiary” of National Securities and Depositories Limited and Sri V.C. Nannapaneni was merely acting as the facilitator of the said transmission process, since he was the nominee to the shares.

Accordingly, the disclosures pertaining to the said shares under Regulations 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Form C of the SEBI (Prohibition of Insider Trading) Regulations, 2015 were enclosed.

This is for your information and records.

Thanking you  
Yours faithfully



Sanjay Nannapaneni

C.C to:  
The Company Secretary, NATCO Pharma Limited

**Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	NATCO Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Sanjay Nannapaneni		
Whether the acquirer belongs to Promoter/Promoter group	Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Ltd & NSE		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of :</b>			
a) Shares carrying voting rights	40,000	0.02	0.02
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	40,000	0.02	0.02
<b>Details of acquisition/sale/ Donation</b>			
a) Shares carrying voting rights acquired/sold	2,86,910	0.16	0.16
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+/-d)	2,86,910	0.16	0.16



<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights	3,26,910	0.18	0.18
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e) Total (a+b+c+d)	3,26,910	0.18	0.18
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Off-Market (as per registered Will Deed, the shares were received from the Nominee of the deceased Shareholder to the legal heir)		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	26 March, 2025		
Equity share capital / total voting capital of the TC before the said acquisition / sale	17,91,09,870		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	17,91,09,870		
Total diluted share/voting capital of the TC after the said acquisition	17,91,09,870		

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



**Signature of the acquirer / seller / Authorised Signatory**

Place: USA

Date: 27 March, 2025

\*\*\*\*\*

**FORM C**

SEBI (Prohibition of Insider Trading) Regulations, 2015  
[Regulation 7 (2) read with Regulation 6(2) – Continual disclosure]

Name of the Company: Natco Pharma Limited  
ISIN of the Company: INE987B01026

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2)

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoter/ member of the promoter group/designated person/Director s/immediate relative to/others etc.)	Securities held prior to acquisition/disposal		Securities acquired/disposed				Securities held post acquisition/disposal		Date of allotment advice/ acquisition of shares/ sale of shares specify		Date of intimation to company	Mode of acquisition / disposal (on market/public/ rights/ preferential offer/ off market/ inter-se transfer, ESOPs etc.)	Exchange on which the trade was executed
		Type of security (For e.g. – Shares, Warrants, Convertible Debentures, rights entitlements, etc.)	No. and % of shareholding	Type of security (For e.g. – Shares, Warrants, Convertible Debentures, rights entitlement, etc.)	No.	Value	Transaction Type (Buy/ Sale/ Pledge/ Revocation/ invocation/ other please specify)	Type of security (For e.g. – Shares, Warrants, Convertible Debentures, rights entitlements, etc.)	No. and % of shareholding	From	To			
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)	(15)
SANJAY NANNAPANENI 7553, RIDGEWOOD LN 60527 USA PAN: DMUPN2150P Contact: 013123154567	Promoter Group	Equity	40,000 & 0.02 %	Equity	2,86,910	---	Other (as per registered Will Deed, the shares were received from the Nominee of the deceased Shareholder to the legal heir)	Equity	3,26,910 & 0.18%	26/03/2025	26/03/2025	27/03/2025	Off market	NA

Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

Trading in derivatives (Specify type of contract, Futures or Options etc.)						Exchange on which the trade was executed
Type of Contract	Contract specifications	Buy		Sell		
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
(16)	(17)	(18)	(19)	(20)	(21)	(22)
NA	NA	NA	NA	NA	NA	NA

Name: Sanjay Nannapaneni

Signature:



Designation: Member of Promoter Group

Date: 27/03/2025

Place: USA